Trials / Conditions / Chronic Myeloid Leukemia, Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase

26 registered clinical trials studyying Chronic Myeloid Leukemia, Chronic Phase — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML NCT06409936	Gruppo Italiano Malattie EMatologiche dell'Adulto	Phase 2
Unknown	Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia NCT05638763	Hospital Universitario Dr. Jose E. Gonzalez	Phase 2
Recruiting	A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in NCT06163430	Terns, Inc.	Phase 1 / Phase 2
Recruiting	A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia NCT06368414	Korean Society of Hematology	Phase 2
Recruiting	Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase NCT06119269	University of Pisa	—
Active Not Recruiting	The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia NCT06233890	Imperial College Healthcare NHS Trust	—
Completed	Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated Wit NCT06516029	Novartis	—
Unknown	"Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a NCT05543161	Sohag University	—
Unknown	Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-gen NCT05311943	Shenzhen Second People's Hospital	Phase 3
Recruiting	Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase NCT05143840	Augusta University	Phase 2
Unknown	Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure NCT04677439	Shenzhen Second People's Hospital	Phase 4
Terminated	Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia NCT04006847	Milton S. Hershey Medical Center	Phase 1 / Phase 2
Active Not Recruiting	Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leuke NCT04147533	Masaryk University	Phase 2
Active Not Recruiting	Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP) NCT04160546	Fundacion CRIS de Investigación para Vencer el Cáncer	Phase 2
Active Not Recruiting	Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors NCT03610971	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Completed	A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase NCT04126681	Ascentage Pharma Group Inc.	Phase 2
Completed	Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients NCT03885830	UNC Lineberger Comprehensive Cancer Center	—
Unknown	Nilotinib for First-line Newly Diagnosed CML-CP Patients NCT03942094	Shenzhen Second People's Hospital	Phase 3
Unknown	A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation NCT03883087	Ascentage Pharma Group Inc.	Phase 2
Completed	Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemi NCT03882281	Ascentage Pharma Group Inc.	Phase 1
Active Not Recruiting	Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERI NCT03722420	Il-Yang Pharm. Co., Ltd.	Phase 3
Recruiting	A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Pre NCT03459534	Il-Yang Pharm. Co., Ltd.	Phase 3
Terminated	Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia NCT03079505	Hamad Medical Corporation	Phase 3
Unknown	Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any NCT03933852	University of Jena	—
Completed	Efficacy and Safety of Nilotinib in CML-CP NCT03332511	Seoul National University Hospital	Phase 4
Completed	Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan NCT02977312	Hikma Pharmaceuticals LLC	—